Galectin Therapeutics Inc
GALT· Nasdaq
GALTGalectin Therapeutics Inc
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001140361-26-032945
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$9.11M | -$7.52M | -$12.37M | -$9.11M |
| EPS Diluted | -$0.14 | -$0.12 | -$0.20 | -$0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Galectin Therapeutics Inc · CIK 1133416 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
